Russian state nuclear operator Rosenergoatom is aiming to increase isotope production volumes and widen the variety it produces as it competes for a share of a global market that could be worth close to $70bn by 2030.
The company said it had drawn up a business programme with Rusatom Healthcare JSC and Isotope JSC to “proceed to the practical stage” of an isotope development programme.
Rosenergoatom said it plans to increase its production of Cobalt-60 (60Co), which is produced in nuclear reactors and can be used for applications ranging from medical radiotherapy to sterilisation of medical equipment and pest insect sterilisation.
The company said it had drawn up a business programme with Rusatom Healthcare JSC and Isotope JSC to “proceed to the practical stage” of an isotope development programme.
Rosenergoatom said it plans to increase its production of Cobalt-60 (60Co), which is produced in nuclear reactors and can be used for applications ranging from medical radiotherapy to sterilisation of medical equipment and pest insect sterilisation.
Want to keep reading?
Register free and get full access to NucNet for 14 days. No card required.
- Daily news briefing on the global nuclear industry
- Weekly, monthly and topical newsletters
- 24/7 coverage during nuclear incidents and safety events
- Full searchable archive, 30,000+ articles since 1991
- SMR and AMR project database
- Analysis, Focus pieces and infographics
- NucNet Style Guide for nuclear reporters and communicators
After the trial, keep a free account for a newsletter and a complimentary Plus article every two weeks. Or see our subscription plans for individuals and organisations.
See subscription options
